Navigation Links
CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:2/26/2008

PALO ALTO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today reported financial results for the fourth quarter and full year ended December 31, 2007.

For the quarter ended December 31, 2007, the Company reported a net loss of $34.1 million, or $0.57 per share. This compares to a net loss of $68.1 million, or $1.18 per share, for the same quarter in 2006 and $34.2 million, or $0.58 per share, for the prior quarter ended September 30, 2007. For the year ended December 31, 2007, the Company reported a net loss of $181.0 million, or $3.05 per share, compared to a net loss of $274.3 million, or $5.49 per share, for the year ended December 31, 2006.

For the quarter ended December 31, 2007, the Company recorded total revenues of $22.4 million which consisted of $20.9 million of net product sales of Ranexa(R) (ranolazine extended-release tablets) and $1.5 million of collaborative research revenue. The $20.9 million of net product sales of Ranexa in the quarter ended December 31, 2007 represents an increase of 14 percent compared to the $18.4 million of net product sales recorded in the prior quarter ended September 30, 2007 and an increase of 132 percent compared to the $9.0 million of net product sales in the same quarter of the prior year. The fourth quarter 2007 collaborative research revenue includes revenue primarily related to the reimbursement of certain regadenoson development costs from our collaborative partner.

For the full year ended December 31, 2007, the Company recorded revenue of $82.8 million, consisting of $66.7 million of net product sales of Ranexa and $16.2 million of collaborative research revenue which includes a $7.0 million milestone payment for submission of a new drug application for regadenoson as well as reimbursement of certain regadenoson development costs from our collaborative partner. This compares to total revenues of $36.8 million for the year ended December 31, 2006, which consisted of $18.4 million of net product sales of Ranexa, $16.9 million of collaborative research revenue primarily related to the reimbursement of certain regadenoson development costs and $1.4 million of co-promotion revenue related to ACEON(R) (perdindopril erbumine) Tablets, which we ceased co-promoting in the quarter ended December 31, 2006.

Costs and expenses were $55.8 million for the quarter ended December 31, 2007. This compares to total costs and expenses of $82.3 million for the same quarter in 2006 and $53.7 million for the prior quarter ended September 30, 2007. The decrease in costs and expenses in the quarter ended December 31, 2007 compared to the same quarter in 2006 was primarily due to lower research and development expenses resulting from lower clinical trial expenses related to the completion of the MERLIN TIMI-36 study of Ranexa and lower regadenoson research and development expenses, a reduction in personnel-related expenses related to the restructuring plan implemented in May 2007, and lower Ranexa sales and marketing expenses. These decreases were partially offset by higher general and administrative costs due to a litigation-related settlement incurred in the quarter ended December 31, 2007, lower general and administrative costs in the quarter ended December 31, 2006 due to insurance reimbursement in connection with now settled litigation and higher cost of sales due to higher net product sales of Ranexa.

The increase of total costs and expenses in the quarter ended December 31, 2007 compared to the prior quarter ended September 30, 2007 was primarily due to higher Ranexa sales and marketing expenses, higher research and development costs associated with various development projects, higher general and administrative costs associated with a litigation-related settlement, and higher cost of sales due to higher net product sales of Ranexa.

For the full year ended December 31, 2007, total costs and expenses were $263.7 million compared to total costs and expenses of $315.3 million for the year ended December 31, 2006. The decrease for the full year ended December 31, 2007 compared to the prior year was primarily due to lower research and development expenses resulting from lower clinical trial expenses related to the completion of the MERLIN TIMI-36 study of Ranexa and lower regadenoson research and development expense, lower Ranexa sales and marketing expenses and lower sales and marketing expenses due to the end of the ACEON(R) co-promotion arrangement and a reduction in personnel-related expenses related to the restructuring plan implemented in May 2007. These decreases were partially offset by higher cost of sales due to higher net product sales of Ranexa and costs associated with the restructuring plan implemented in May 2007, which included severance benefits, stock-based compensation expense related to accelerated vesting of employee stock options and forfeiture of certain stock appreciation rights and costs related to excess leased office space.

At December 31, 2007, the Company had cash, cash equivalents, marketable securities and restricted cash of $179.0 million compared to $199.5 million at September 30, 2007. Our total cash utilized for the quarter ended December 31, 2007 was $20.5 million. This compares to our cash utilized for the prior quarter of $24.2 million.

Company management will webcast a conference call on February 26, 2008 at 5:00 p.m. EST, 2:00 p.m. PST, on the Company's website. To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

CV THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS DATA

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three months ended Year ended

December 31, December 31,

2007 2006 2007 2006

Revenues:

Product sales, net $20,928 $9,029 $66,651 $18,423

Collaborative research 1,474 3,640 16,172 16,923

Co-promotion - - - 1,439

Total revenues 22,402 12,669 82,823 36,785

Costs and expenses (1):

Cost of sales 3,131 1,236 9,689 2,752

Research and

development 19,710 38,102 94,742 135,254

Selling, general and

administrative 32,950 42,956 152,496 177,264

Restructuring charges (11) - 6,763 -

Total costs and expenses 55,780 82,294 263,690 315,270

Loss from operations (33,378) (69,625) (180,867) (278,485)

Other income (expense), net:

Interest and other

income, net 2,421 4,731 12,533 16,832

Interest expense (3,174) (3,166) (12,672) (12,667)

Total other income

(expense), net (753) 1,565 (139) 4,165

Net loss $(34,131) $(68,060) $(181,006) $(274,320)

Basic and diluted net

loss per share $(0.57) $(1.18) $(3.05) $(5.49)

Shares used in computing

basic and diluted net

loss per share 59,696 57,823 59,335 49,983

(1) Costs and expenses include non-recurring stock-based compensation

expense related to the acceleration of stock options and the voluntary

forfeiture of stock appreciation rights as follows:

Cost of sales $- $- $109 $-

Research and development - - 4,606 -

Selling, general and

administrative - - 8,471 -

Total non-recurring

stock-based compensation

charges $- $- $13,186 $-

Reconciliation of GAAP Items to Non-GAAP Items (2):

Net loss, as reported $(34,131) $(68,060) $(181,006) $(274,320)

Adjustments:

Non-recurring stock-based

compensation charges - - 13,186 -

Restructuring charges (11) - 6,763 -

Net loss, non-GAAP $(34,142) $(68,060) $(161,057) $(274,320)

Basic and diluted net

loss per share,

as reported $(0.57) $(1.18) $(3.05) $(5.49)

Adjustments $0.00 $- $0.34 $-

Basic and diluted net

loss per share,

non-GAAP(3) $(0.57) $(1.18) $(2.71) $(5.49)

Shares used in

computing basic and

diluted net loss

per share 59,696 57,823 59,335 49,983

(2) CVT believes that the non-GAAP financial measures presented in this

press release are useful for investors because these measures provide

added insight into CVT's performance by focusing on results generated

by its ongoing operations. In addition, CVT uses these non-GAAP

financial measures when assessing the performance of its ongoing

operations, in making resource allocation decisions and for planning

and forecasting.

(3) The values shown above are exact; totals may not appear to sum due to

rounding.

CONSOLIDATED BALANCE SHEET DATA

(in thousands)

(unaudited)

December 31, December 31,

2007 2006

Assets:

Cash, cash equivalents,

and marketable securities $174,245 $325,226

Other current assets 41,825 40,269

Total current assets 216,070 365,495

Property and equipment, net 19,131 23,919

Other assets 23,635 32,042

Total assets $258,836 $421,456

Liabilities and stockholders' deficit:

Current liabilities $39,183 $62,247

Convertible subordinated notes 399,500 399,500

Other long-term obligations 5,551 5,507

Stockholders' deficit (185,398) (45,798)

Total liabilities and stockholders' deficit $258,836 $421,456


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
5. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
6. Ocera Therapeutics Closes $35.5 Million Series C Financing
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
8. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
9. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
10. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
11. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... Triangle Park, North Carolina (PRWEB) , ... November 30, 2016 , ... ... (IUPAC) approved the names and symbols for four elements: nihonium (Nh), moscovium (Mc), ... Following a 5-month period of public review, the names earlier proposed by the discoverers ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):